Sunday, August 27, 2006

"One Pfizer" - Kindler's halo effect


“There is definitely a halo effect (on Kindler),” said David Moskowitz, an analyst at Friedman, Billings, Ramsey. “But investors are impatient. The honeymoon will be short.”

More of Kindler's PR "charm offensive" here.

He will have to get a move on sorting out his "to do" list.

The US Exubera launch must be weighing heavily on his mind.

This product is not a guaranteed success by any means!

No comments: